Preventive therapy for tuberculosis in HIV infected individuals

Area of Science:

• Infectious Diseases
• Public Health
• HIV/AIDS Research

Background:

• HIV infection significantly increases the risk of developing tuberculosis (TB).
• Preventive therapy (chemoprophylaxis) with antituberculosis drugs is being reconsidered for HIV-infected individuals.
• Ruling out active TB before initiating preventive therapy is essential.

Purpose of the Study:

• To evaluate the role and optimal implementation of tuberculosis preventive therapy in HIV-positive individuals.
• To define the target population for chemoprophylaxis among those with HIV.
• To determine the optimal duration and monitoring strategies for TB preventive therapy.

Main Methods:

• Identifying target populations: Mantoux (PPD) positive HIV-seropositive individuals without active TB, and potentially PPD negative individuals in high TB prevalence areas.
• Recommending isoniazid preventive therapy for greater than six months (daily or twice weekly).
• Emphasizing regular monitoring for drug adherence, toxicity, and TB development.

Main Results:

• Preventive therapy, particularly isoniazid for over six months, provides significant protection against tuberculosis in HIV-infected individuals.
• Widespread implementation can substantially reduce TB morbidity and impact mortality.
• Preventive therapy should be integrated into care packages at voluntary counselling and testing centres.

Conclusions:

• Tuberculosis preventive therapy is a vital component of care for HIV-positive individuals, especially in resource-limited settings.
• Optimal duration and adherence monitoring are key to maximizing the effectiveness of isoniazid preventive therapy.
• Integrating TB preventive therapy with other HIV care services improves overall patient outcomes.